Analysts predict that NeoGenomics, Inc. (NASDAQ:NEO) will report $0.06 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for NeoGenomics’ earnings, with estimates ranging from $0.04 to $0.07. NeoGenomics posted earnings of $0.05 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 20%. The business is scheduled to issue its next quarterly earnings results on Tuesday, July 23rd.

According to Zacks, analysts expect that NeoGenomics will report full year earnings of $0.26 per share for the current year, with EPS estimates ranging from $0.22 to $0.30. For the next financial year, analysts expect that the firm will post earnings of $0.39 per share, with EPS estimates ranging from $0.29 to $0.60. Zacks’ earnings per share calculations are an average based on a survey of research firms that follow NeoGenomics.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, April 30th. The medical research company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. The firm had revenue of $95.60 million during the quarter, compared to the consensus estimate of $89.71 million. NeoGenomics had a positive return on equity of 3.07% and a negative net margin of 0.14%. The firm’s quarterly revenue was up 50.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.04 earnings per share.

Several analysts recently weighed in on NEO shares. Needham & Company LLC lifted their price objective on NeoGenomics from $19.00 to $22.00 and gave the company a “buy” rating in a report on Friday, March 29th. Zacks Investment Research upgraded NeoGenomics from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a research note on Tuesday, March 5th. BidaskClub upgraded NeoGenomics from a “hold” rating to a “buy” rating in a research note on Tuesday, January 29th. Finally, CIBC upgraded NeoGenomics from a “neutral” rating to an “outperform” rating and dropped their price target for the stock from $18.00 to $15.00 in a research note on Tuesday, March 12th. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $20.00.

In related news, insider George Cardoza sold 151,676 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $22.82, for a total value of $3,461,246.32. Following the sale, the insider now owns 452,507 shares in the company, valued at $10,326,209.74. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Robert J. Shovlin sold 186,014 shares of the company’s stock in a transaction that occurred on Wednesday, February 27th. The stock was sold at an average price of $18.96, for a total value of $3,526,825.44. Following the completion of the sale, the insider now owns 40,166 shares in the company, valued at approximately $761,547.36. The disclosure for this sale can be found here. Insiders have sold 602,400 shares of company stock worth $12,693,858 in the last 90 days. Insiders own 12.20% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its position in NeoGenomics by 150.5% in the 1st quarter. BlackRock Inc. now owns 13,825,064 shares of the medical research company’s stock worth $282,861,000 after purchasing an additional 8,305,417 shares in the last quarter. Vanguard Group Inc boosted its position in NeoGenomics by 24.0% in the 3rd quarter. Vanguard Group Inc now owns 3,839,641 shares of the medical research company’s stock worth $58,939,000 after purchasing an additional 743,245 shares in the last quarter. Vanguard Group Inc. boosted its position in NeoGenomics by 24.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,839,641 shares of the medical research company’s stock worth $58,939,000 after purchasing an additional 743,245 shares in the last quarter. Eagle Asset Management Inc. boosted its position in NeoGenomics by 19.0% in the 1st quarter. Eagle Asset Management Inc. now owns 2,705,536 shares of the medical research company’s stock worth $55,355,000 after purchasing an additional 431,393 shares in the last quarter. Finally, Brown Advisory Inc. boosted its position in NeoGenomics by 66.2% in the 4th quarter. Brown Advisory Inc. now owns 2,441,468 shares of the medical research company’s stock worth $30,787,000 after purchasing an additional 972,288 shares in the last quarter. Institutional investors and hedge funds own 76.36% of the company’s stock.

Shares of NEO stock traded up $0.35 on Friday, hitting $23.46. The stock had a trading volume of 19,918 shares, compared to its average volume of 1,140,191. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.59 and a quick ratio of 1.46. The company has a market capitalization of $2.21 billion, a P/E ratio of 180.15 and a beta of 0.91. NeoGenomics has a one year low of $11.00 and a one year high of $23.85.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

See Also: Diversification in Investing

Get a free copy of the Zacks research report on NeoGenomics (NEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.